Your participation helps us learn about the long-term effects of common medications on reducing heart attack and stroke in people with type 2 diabetes. We truly appreciate your time and commitment to help advance care for people with type 2 diabetes.

All study medications are approved by the FDA to treat type 2 diabetes.

A computer will randomly assign you to take:

• An SGLT2 inhibitor such as Jardiance, Farxiga, Invokana

• A GLP-1 receptor agonist such as Victoza, Trulicity, Ozempic, Rybelsus

You can choose the medication within the class assigned to you. This choice may be based on your insurance coverage or your preference.

All participants will be randomized to an active drug. This study does not include a placebo group/arm.

This study lasts through 2029 because we want to see what the long-term effects of the medications are on important outcomes like heart attack and stroke.

Our study team will work with your regular health care provider to fit the study medication into your usual diabetes care. Your current diabetes medications may be adjusted.

Medications and lab tests will be billed to your insurance company. Our study team will help assess your insurance coverage.

All participants will pay for the medication through regular health insurance, just like other prescription medications.

These medications can lower blood sugar, lower A1C, help with weight loss and prevent heart problems.

You will be paid $500 for each year that you take part in the study.

Participating Study Locations. For contact information on each site, please visit the Study Locations page.

Columbia University

Duke University

Essentia Health

Johns Hopkins University

University of Missouri

Medical University of South Carolina

Vanderbilt University

Medical College of Wisconsin